Cara Therapeutics to Webcast Presentation at 26th Annual Piper Jaffray Healthcare Conference
25 nov. 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Webcast Presentation at 2014 Stifel Healthcare Conference
11 nov. 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Reports Third Quarter 2014 Financial Results
10 nov. 2014 16h01 HE
|
Cara Therapeutics
Reported positive top-line data from human abuse liability trial for I.V. CR845
Phase 3 registration trials for I.V. CR845 expected to initiate in early 2015
Conference call today at...
Cara Therapeutics to Announce Third Quarter 2014 Financial Results on November 10, 2014
03 nov. 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Announces Positive Results From Human Abuse Liability Trial of Peripheral Opioid for Acute Pain, I.V. CR845
29 oct. 2014 07h00 HE
|
Cara Therapeutics
Trial meets primary endpoint with I.V. CR845 showing highly statistically significant reductions (p <0.0001) in scores for "drug liking," as well as "feeling high", "overall liking", and "take...
Cara Therapeutics Announces the Unexpected Death of Chief Medical Officer Dr. Robert Medve
27 oct. 2014 08h45 HE
|
Cara Therapeutics
SHELTON, Conn., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Sponsor Symposium at American Academy of Pain Management 2014 Annual Clinical Meeting
17 sept. 2014 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Reports Second Quarter 2014 Financial Results
07 août 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus
06 août 2014 08h00 HE
|
Cara Therapeutics
Two-part study to evaluate safety, pharmacokinetics and anti-itch effects in hemodialysis patients
Top-line data expected in first half of 2015
SHELTON, Conn., Aug. 6, 2014 (GLOBE...
Cara Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014
31 juil. 2014 16h01 HE
|
Cara Therapeutics
SHELTON, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...